CL2012003450A1 - Una formulacion en polvo seca inhalable que comprende como ingrediente activo particulas micronizadas de un compuesto antimuscarinico derivado de 1-azonia-biciclo[2.2.2]octano y particulas de un vehiculo; inhalador de polvo seco que la comprende, util para la prevencion y/o el tratamiento de una enfermedad respiratoria tal como asma y epoc. - Google Patents
Una formulacion en polvo seca inhalable que comprende como ingrediente activo particulas micronizadas de un compuesto antimuscarinico derivado de 1-azonia-biciclo[2.2.2]octano y particulas de un vehiculo; inhalador de polvo seco que la comprende, util para la prevencion y/o el tratamiento de una enfermedad respiratoria tal como asma y epoc.Info
- Publication number
- CL2012003450A1 CL2012003450A1 CL2012003450A CL2012003450A CL2012003450A1 CL 2012003450 A1 CL2012003450 A1 CL 2012003450A1 CL 2012003450 A CL2012003450 A CL 2012003450A CL 2012003450 A CL2012003450 A CL 2012003450A CL 2012003450 A1 CL2012003450 A1 CL 2012003450A1
- Authority
- CL
- Chile
- Prior art keywords
- dry powder
- particles
- epoc
- azonia
- bicyclo
- Prior art date
Links
- 239000002245 particle Substances 0.000 title abstract 4
- 239000004480 active ingredient Substances 0.000 title abstract 2
- 230000001022 anti-muscarinic effect Effects 0.000 title abstract 2
- 208000006673 asthma Diseases 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 229940112141 dry powder inhaler Drugs 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title abstract 2
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000000843 powder Substances 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title abstract 2
- SBYHFKPVCBCYGV-UHFFFAOYSA-N quinuclidine Chemical compound C1CC2CCN1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-N 0.000 title abstract 2
- 208000023504 respiratory system disease Diseases 0.000 title abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Otolaryngology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Una formulación en polvo seca inhalable que comprende como ingrediente activo partículas micronizadas de un compuesto antimuscarínico derivado de 1-azonia-biciclo[2.2.2]octano y partículas de un vehículo; inhalador de polvo seco que la comprende, útil para la prevención y/o el tratamiento de una enfermedad respiratoria tal como asma y epoc.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10166903 | 2010-06-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2012003450A1 true CL2012003450A1 (es) | 2013-03-15 |
Family
ID=42942112
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2012003450A CL2012003450A1 (es) | 2010-06-22 | 2012-12-06 | Una formulacion en polvo seca inhalable que comprende como ingrediente activo particulas micronizadas de un compuesto antimuscarinico derivado de 1-azonia-biciclo[2.2.2]octano y particulas de un vehiculo; inhalador de polvo seco que la comprende, util para la prevencion y/o el tratamiento de una enfermedad respiratoria tal como asma y epoc. |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20110308519A1 (es) |
| EP (1) | EP2585047A1 (es) |
| JP (1) | JP2013529606A (es) |
| KR (1) | KR20130111967A (es) |
| CN (1) | CN102946868B (es) |
| AR (1) | AR081967A1 (es) |
| AU (1) | AU2011269238A1 (es) |
| BR (1) | BR112012032330A2 (es) |
| CA (1) | CA2803418A1 (es) |
| CL (1) | CL2012003450A1 (es) |
| CO (1) | CO6640319A2 (es) |
| EA (1) | EA201291306A1 (es) |
| MA (1) | MA34326B1 (es) |
| MX (1) | MX2012014541A (es) |
| NZ (1) | NZ604983A (es) |
| PE (1) | PE20130282A1 (es) |
| PH (1) | PH12012502404A1 (es) |
| SG (1) | SG186427A1 (es) |
| TN (1) | TN2012000566A1 (es) |
| TW (1) | TW201204412A (es) |
| UA (1) | UA107499C2 (es) |
| WO (1) | WO2011160920A1 (es) |
| ZA (1) | ZA201209682B (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2154136A1 (en) | 2008-08-08 | 2010-02-17 | CHIESI FARMACEUTICI S.p.A. | Quinuclidine carbonate derivatives and medicinal compositions thereof |
| EP2206712A1 (en) | 2008-12-23 | 2010-07-14 | CHIESI FARMACEUTICI S.p.A. | "Alkaloid aminoester derivatives and medicinal composition thereof" |
| BR112012032332A2 (pt) * | 2010-06-22 | 2016-11-08 | Chiesi Farma Spa | composto, uso de um composto, composição farmacêutica, combinação de um composto e dispositivo |
| ES2545812T3 (es) * | 2010-06-22 | 2015-09-16 | Chiesi Farmaceutici S.P.A. | Derivados aminoéster de alcaloides y composición medicinal de estos |
| TR201205852A2 (tr) * | 2011-06-02 | 2012-12-21 | Bi̇lgi̇ç Mahmut | Geliştirilmiş yeni kuru toz formülasyonu. |
| TR201105367A2 (tr) * | 2011-06-02 | 2012-12-21 | Bi̇lgi̇ç Mahmut | Akış özellikleri geliştirilmiş bir kuru toz formülasyonu. |
| RU2628082C2 (ru) | 2011-12-30 | 2017-08-14 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Хинуклидиновые эфиры 1-азагетероциклилуксусной кислоты в качестве антимускариновых средств, способ их получения и их лекарственные композиции |
| ES2814336T3 (es) | 2012-04-13 | 2021-03-26 | Glaxosmithkline Ip Dev Ltd | Partículas de agregado |
| WO2014007768A1 (en) | 2012-07-05 | 2014-01-09 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Dry powder inhaler compositions comprising long acting muscorinic antagonists |
| WO2014083026A1 (en) * | 2012-11-30 | 2014-06-05 | F. Hoffmann-La Roche Ag | Inhibitors of bruton's tyrosine kinase |
| PT3019153T (pt) | 2013-07-11 | 2018-12-04 | Chiesi Farm Spa | Formulação de pó seco que compreende um anticolinérgico, um corticosteroide e um beta-adrenérgico para administração por inalação |
| GB201321717D0 (en) * | 2013-12-09 | 2014-01-22 | Pharmachemie Bv | Inhalable Medicaments |
| GB201402556D0 (en) | 2014-02-13 | 2014-04-02 | Crystec Ltd | Improvements relating to inhalable particles |
| TWI731891B (zh) * | 2015-11-16 | 2021-07-01 | 義大利商吉斯藥品公司 | 含有抗膽鹼劑、皮質類固醇及β-腎上腺素之乾粉配方之製備方法 |
| CN114425049A (zh) * | 2016-07-04 | 2022-05-03 | 正大天晴药业集团股份有限公司 | 一种可吸入干粉形式的药物组合物所用的载体的制备方法 |
| EP3910324A1 (en) | 2018-08-07 | 2021-11-17 | Norton (Waterford) Limited | Application of raman spectroscopy for the manufacture of inhalation powders |
| IT201800007928A1 (it) * | 2018-08-07 | 2020-02-07 | Sofar Spa | Composizione contenente un agente mucolitico per il trattamento di ipersecrezione di muco e dispositivo per il suo dosaggio |
| IL300652A (en) | 2020-08-14 | 2023-04-01 | Norton Waterford Ltd | Inhalable formulation of fluticasone propionate and albuterol sulfate |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1158958B1 (en) | 1999-03-05 | 2007-06-06 | CHIESI FARMACEUTICI S.p.A. | Improved powdery pharmaceutical compositions for inhalation |
| PE20011227A1 (es) | 2000-04-17 | 2002-01-07 | Chiesi Farma Spa | Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros |
| EP1296651B2 (en) | 2000-06-27 | 2019-07-17 | Vectura Limited | Method of making particles for use in a pharmaceutical composition |
| KR100869722B1 (ko) | 2000-12-22 | 2008-11-21 | 알미랄 에이쥐 | 퀴누클리딘 카르바메이트 유도체 및 ｍ3 길항제로서 그의사용 |
| RS52522B (sr) | 2001-12-20 | 2013-04-30 | Chiesi Farmaceutici S.P.A. | Derivati 1-alkil-1-azoniabiciklo/2.2.2./oktan karbamata i njihova upotreba kao antagonista muskarinskih receptora |
| DE60239639D1 (de) | 2002-07-31 | 2011-05-12 | Chiesi Farma Spa | Pulverinhalator |
| NZ538965A (en) * | 2002-08-21 | 2006-11-30 | Norton Healthcare Ltd | Dry powder inhalation compositions |
| PE20060259A1 (es) * | 2004-04-27 | 2006-03-25 | Glaxo Group Ltd | Compuestos de quinuclidina como antagonistas del receptor de acetilcolina muscarinico |
| GB0424284D0 (en) * | 2004-11-02 | 2004-12-01 | Novartis Ag | Organic compounds |
| EP1882691A1 (en) * | 2006-07-26 | 2008-01-30 | CHIESI FARMACEUTICI S.p.A. | Quinuclidine derivatives as M3 antagonists |
| GB0811099D0 (en) * | 2008-06-17 | 2008-07-23 | Astrazeneca Ab | New combination 376 |
-
2011
- 2011-05-30 CN CN201180030601.1A patent/CN102946868B/zh not_active Expired - Fee Related
- 2011-05-30 MA MA35474A patent/MA34326B1/fr unknown
- 2011-05-30 MX MX2012014541A patent/MX2012014541A/es not_active Application Discontinuation
- 2011-05-30 NZ NZ604983A patent/NZ604983A/en not_active IP Right Cessation
- 2011-05-30 EA EA201291306A patent/EA201291306A1/ru unknown
- 2011-05-30 PE PE2012002468A patent/PE20130282A1/es not_active Application Discontinuation
- 2011-05-30 WO PCT/EP2011/058804 patent/WO2011160920A1/en not_active Ceased
- 2011-05-30 KR KR1020127033556A patent/KR20130111967A/ko not_active Withdrawn
- 2011-05-30 AU AU2011269238A patent/AU2011269238A1/en not_active Abandoned
- 2011-05-30 UA UAA201214589A patent/UA107499C2/uk unknown
- 2011-05-30 EP EP11724158.8A patent/EP2585047A1/en not_active Withdrawn
- 2011-05-30 PH PH1/2012/502404A patent/PH12012502404A1/en unknown
- 2011-05-30 BR BR112012032330A patent/BR112012032330A2/pt not_active IP Right Cessation
- 2011-05-30 JP JP2013515798A patent/JP2013529606A/ja not_active Withdrawn
- 2011-05-30 CA CA2803418A patent/CA2803418A1/en not_active Abandoned
- 2011-05-30 SG SG2012094264A patent/SG186427A1/en unknown
- 2011-06-21 AR ARP110102149A patent/AR081967A1/es unknown
- 2011-06-21 TW TW100121556A patent/TW201204412A/zh unknown
- 2011-06-22 US US13/165,955 patent/US20110308519A1/en not_active Abandoned
-
2012
- 2012-11-30 TN TNP2012000566A patent/TN2012000566A1/en unknown
- 2012-12-06 CL CL2012003450A patent/CL2012003450A1/es unknown
- 2012-12-20 ZA ZA2012/09682A patent/ZA201209682B/en unknown
- 2012-12-20 CO CO12230869A patent/CO6640319A2/es active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| BR112012032330A2 (pt) | 2016-11-08 |
| EP2585047A1 (en) | 2013-05-01 |
| MA34326B1 (fr) | 2013-06-01 |
| AU2011269238A1 (en) | 2013-01-10 |
| SG186427A1 (en) | 2013-01-30 |
| UA107499C2 (uk) | 2015-01-12 |
| AR081967A1 (es) | 2012-10-31 |
| TN2012000566A1 (en) | 2014-04-01 |
| CO6640319A2 (es) | 2013-03-22 |
| WO2011160920A1 (en) | 2011-12-29 |
| TW201204412A (en) | 2012-02-01 |
| KR20130111967A (ko) | 2013-10-11 |
| CN102946868A (zh) | 2013-02-27 |
| MX2012014541A (es) | 2013-01-29 |
| NZ604983A (en) | 2014-07-25 |
| CA2803418A1 (en) | 2011-12-29 |
| EA201291306A1 (ru) | 2013-05-30 |
| JP2013529606A (ja) | 2013-07-22 |
| ZA201209682B (en) | 2014-03-26 |
| CN102946868B (zh) | 2014-10-29 |
| PE20130282A1 (es) | 2013-03-25 |
| US20110308519A1 (en) | 2011-12-22 |
| PH12012502404A1 (en) | 2013-02-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2012003450A1 (es) | Una formulacion en polvo seca inhalable que comprende como ingrediente activo particulas micronizadas de un compuesto antimuscarinico derivado de 1-azonia-biciclo[2.2.2]octano y particulas de un vehiculo; inhalador de polvo seco que la comprende, util para la prevencion y/o el tratamiento de una enfermedad respiratoria tal como asma y epoc. | |
| CL2013000293A1 (es) | Una formulacion en polvo seco inhalable que comprende como ingrediente activo particulas micronizadas de un compuesto inhibidor de fosfodiesterasa-4, como enantiomero (-) y particulas de un vehiculo; inhalador de polvo seco y envase que comprende a la formulacion, util para la prevencion y/o el tratamiento del asma y epoc. | |
| WO2012078593A3 (en) | Lysophosphatidic acid receptor antagonists and their use in the treatment fibrosis | |
| WO2012024620A3 (en) | Autotaxin inhibitors and uses thereof | |
| MY183615A (en) | Inhalable pharmaceutical compositions | |
| GT201400016A (es) | Indazoles | |
| HK1221653A1 (zh) | 用於呼吸递送三种或更多种活性剂的组合物、方法和系统 | |
| WO2013112959A8 (en) | Antifibrotic compounds and uses thereof | |
| AR083208A1 (es) | Uso de estearato de magnesio en formulaciones de polvo seco para inhalacion | |
| CY1120684T1 (el) | Σκευασμα ξηρης σκονης που περιλαμβανει ενα κορτικοστεροειδες και ενα βητα-αδρενεργικο για χορηγηση δια εισπνοης | |
| WO2013114371A8 (en) | Dry powder formulations of dnase i | |
| WO2014016548A3 (en) | Pharmaceutical composition comprising olodaterol and one or more further active pharmaceutical ingredient | |
| PH12014501545A1 (en) | Stable pharmaceutical formulation for oral administration comprising levocetirizine or a pharmaceutically acceptable salt thereof, and montelukast or a pharmaceutically acceptable salt thereof | |
| CL2014003211A1 (es) | Composicion farmaceutica para inhalacion que comprende aclidinio, con lactosa, que proporciona una dosis de 322 ug de base libre y aprox 140 ug de bromuro de aclidinio; un metodo para tratar una afeccion respiratoria seleccionada de asma y epoc; uso de la composicion; y un dispositivo inhalador de polvo seco calibrado que la comprende | |
| WO2012085284A3 (en) | High drug load pharmaceutical formulations comprising dronedarone and its pharmaceutically acceptable salts | |
| WO2011093818A3 (en) | Pharmaceutical compositions comprising salmeterol and fluticasone | |
| DOP2010000122A (es) | Terapia de combinacion | |
| TR201007250A2 (tr) | Selobioz içeren formülasyon. | |
| EP2142209A4 (en) | DISPERSIONS IN A PARTICULATE AEROSOL WITH ACTIVE PHARMACEUTICAL INGREDIENTS | |
| TN2013000015A1 (en) | Dry powder formulation comprising a phosphodiesterase inhibitor | |
| WO2013175347A3 (en) | Compositions and methods for treatment of respiratory disorders | |
| WO2013035997A3 (en) | Pharmaceutical composition for preventing or treating alopecia comprising tianeptine or its salt | |
| TR201000731A2 (tr) | Tiotropyum ve flutikazon içeren kuru toz formundaki farmasötik kompozisyon. | |
| TR201000624A2 (tr) | Tiotropium ve flutikazon içeren kuru toz formundaki farmasötik kompozisyon. | |
| TR201000621A2 (tr) | Tiotropium ve budesonid içeren kuru toz formundaki farmasötik kompozisyon |